Desde la última actualización de junio de 2022, Health Canada ha aprobado tres biosimilares más (Myxredlin, Rymti, Elonox) en 2022 [1].
- INICIO
-
Genéricos
Novedades
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Investigación
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
- Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
-
Biosimilares
Novedades
- EMA recommends approval of biosimilar bevacizumab Avzivi
- FDA approves first interchangeable aflibercept biosimilars to treat macular degeneration
- FDA approves ustekinumab trastuzumab, and tocilizumab biosimilars
- Actualización de los biosimilares aprobados por Health Canada en 2023
Investigación
- Unveiling key clinical findings for denosumab biosimilar candidates
- Topline results for Polpharma Biologics’ vedolizumab biosimilar candidate
- Comparing biosimilar adoption: Medicare Advantage versus traditional Medicare
- Cuestionando la necesidad de evaluaciones de sensibilidad étnica para anticuerpos monoclonales biosimilares
General
- Desafíos y avances en el registro de biosimilares en América Latina
- Canada's path to biosimilar adoption and healthcare accessibility: insights from British Columbia
- Disruption in the US adalimumab market
- Addressing the persistent gap in Medicare access to Humira biosimilars
- MORE EDITORIAL SECTIONS
- Search
Comments (0)
Post your comment